Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of kidney maturation on aminoglycoside exposure in term-born pediatric patients: an in silico study.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Retraction notice to "Exploring the molecular mechanisms of MSC-derived exosomes in Alzheimer's disease: Autophagy, insulin and the PI3K/Akt/mTOR signaling pathway" [Biomedicine & Pharmacotherapy 176 (2024) 116836].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Infection following foot and ankle surgery : a subanalysis of data captured from the UK Foot and Ankle Thromboembolism (FATE) audit.

The bone & joint journal·2026
Same author

Targeting alpha 7 nicotinic acetylcholine receptors by galantamine alleviates doxorubicin-induced cardiotoxicity <i>via</i> modulation of PI3K/AKT, Bax/Bcl-2, and NF-κB/TNF-α pathways.

Immunopharmacology and immunotoxicology·2026
Same author

Ameliorative impact of aprepitant on cisplatin testicular toxicity: Dual regulation of PI3K/AKT pro-survival signaling and Bax/cytochrome c/caspase-3 apoptotic signaling.

Life sciences·2026
Same author

The renoprotective effect of d-limonene against cisplatin-induced acute kidney injury: targeting Nrf2/HO-1 and NLRP-3 inflammasome signaling pathways.

Molecular and cellular biochemistry·2026

Related Experiment Video

Updated: Apr 12, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K

3-Formylchromone attenuates urethane-induced lung carcinogenesis and enhances gefitinib anti-tumor response via

Amany A Azouz1, Ahmed Khalaf1, Rasha Hussein2

  • 1Department of Pharmacology & Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.

Toxicology Mechanisms and Methods
|April 11, 2026
PubMed
Summary

3-formylchromone shows anti-tumor effects against lung cancer and enhances gefitinib efficacy. This combination therapy may improve treatment outcomes and overcome resistance to tyrosine kinase inhibitors (TKIs).

Keywords:
3-formylchromoneIL-6JAK1/STAT3 signalingLung cancercyclin D1

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K

Related Experiment Videos

Last Updated: Apr 12, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Lung cancer is a leading cause of cancer mortality worldwide.
  • Reduced sensitivity to tyrosine kinase inhibitors (TKIs) like gefitinib necessitates novel therapeutic strategies.
  • Investigating compounds that can enhance TKI efficacy and overcome resistance is crucial for improved lung cancer management.

Purpose of the Study:

  • To evaluate the anti-tumor potential of 3-formylchromone against lung cancer.
  • To assess the modulatory effect of 3-formylchromone on gefitinib response in lung cancer.
  • To elucidate the underlying molecular mechanisms, including the IL-6/JAK1/STAT3 signaling pathway.

Main Methods:

  • In vitro cytotoxicity assessment using MTT assay on A549 lung cancer cells.
  • In vivo evaluation of 3-formylchromone and gefitinib combination therapy in a urethane-induced lung cancer mouse model.
  • Analysis of IL-6 levels, JAK1/STAT3 signaling activation, and cyclin D1 protein expression.

Main Results:

  • 3-formylchromone and gefitinib demonstrated cytotoxic effects against A549 cells.
  • In vivo, 3-formylchromone down-regulated lung IL-6, repressed JAK1/STAT3 signaling, and reduced cyclin D1 expression.
  • Combination therapy significantly reduced tumor burden and pathological lung changes, outperforming gefitinib alone.

Conclusions:

  • 3-formylchromone exhibits significant anti-tumor activity in lung cancer models.
  • 3-formylchromone enhances gefitinib efficacy, potentially by inhibiting the IL-6/JAK1/STAT3/cyclin D1 signaling pathway.
  • This compound represents a promising therapeutic candidate for improving lung cancer management and overcoming gefitinib resistance.